PF-05190457

DRUG4 trials

Sponsors

Pfizer, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions

Alcohol DependenceAlcohol DrinkingAlcohol Drinking Related ProblemsAlcohol-Related DisordersAlcoholismDiabetes Mellitus, Type 2Diabetes Mellitus, Type II

Phase 1

Single Dose Escalation Study of PF-05190457 in Healthy Volunteers

CompletedNCT01247896

PfizerDiabetes Mellitus, Type II

Start: 2010-12-31End: 2011-06-30Target: 26Updated: 2011-07-06

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

CompletedNCT01522807

PfizerDiabetes Mellitus, Type 2

Start: 2011-09-30End: 2011-11-30Updated: 2012-02-01

A Novel Compound for Alcoholism Treatment

CompletedNCT02039349

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcohol Dependence, Alcohol Drinking, Alcohol Drinking Related Problems +2

Start: 2014-01-03End: 2017-12-24Updated: 2019-12-16

Phase 2

A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II

TerminatedNCT02707055

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcoholism

Start: 2016-06-15End: 2020-09-09Updated: 2022-03-16

Related Papers

A randomized, double-blind, placebo-controlled study of a GHSR blocker in people with alcohol use disorder

JCI Insight2024-12-195 citations

A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers.

2020-11-0510 citations

Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers.

2019-09-2321 citations